AstraZeneca Sees Prilosec OTC As “Neutral To Beneficial” For Nexium Sales
This article was originally published in The Tan Sheet
Executive Summary
The effect Prilosec OTC has on health plan formularies may provide an upshot for sales of AstraZeneca's follow-on Nexium (esomeprazole), CFO Jonathan Symonds said during an Oct. 23 earnings call